Trial
NCT06767956
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Pittsburgh
Collaborators
Bristol-Myers Squibb
Condition
Non Hodgkin Lymphoma
Intervention
GOLCADOMIDE
Why stopped
IND Sponsor-Investigator left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-13